The study will include up to 180 eyes at 10 sites in the United States, Canada, Spain, and Israel. The primary outcome is IOP, and the secondary outcome is aderse eent frequency.

• 研究将包括美国，加拿大，西班牙及以色列的10个地点的180只眼睛。主要评价指标是眼内压，其次是出现不良反应的频率。